Grifols (GRFS) EBITDA Margin Growth (3y) (2013 - 2020)
Grifols (GRFS) EBITDA Margin Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 470.67 Bn | 464.10 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 378.00 Bn | 370.86 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 842.00 |
| 5 | Astrazeneca | 257.85 Bn | 252.95 Bn | 12.86 Bn | -95.00 |
| 6 | Amgen | 236.64 Bn | 222.65 Bn | 7.24 Bn | -347.00 |
| 7 | Gilead Sciences | 182.27 Bn | 179.09 Bn | 6.22 Bn | -15,844.00 |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 20,333.00 |
| 9 | Gsk | 106.20 Bn | 102.03 Bn | 8.24 Bn | -2,411.00 |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 3,992.00 |
| Dec 31, 2019 | 4,199.00 |
| Mar 31, 2019 | 4,186.00 |
| Dec 31, 2018 | -10,262.00 |
| Jun 30, 2018 | 24.00 |
| Mar 31, 2018 | -175.00 |
| Dec 31, 2017 | -652.00 |
| Jun 30, 2017 | -2,507.00 |
| Mar 31, 2017 | -345.00 |
| Dec 31, 2016 | 2,836.00 |
| Sep 30, 2016 | -400.00 |
| Jun 30, 2016 | -474.00 |
| Mar 31, 2016 | 205.00 |
| Dec 31, 2015 | 10,939.00 |
| Sep 30, 2015 | -122.00 |
| Jun 30, 2015 | -220.00 |
| Mar 31, 2015 | 516.00 |
| Dec 31, 2014 | 1,504.00 |
| Sep 30, 2014 | 574.00 |
| Jun 30, 2014 | -3,434.00 |